دورية أكاديمية
Neoadjuvant systemic therapy for hepatocellular carcinoma.
| العنوان: | Neoadjuvant systemic therapy for hepatocellular carcinoma. |
|---|---|
| المؤلفون: | Chick RC; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, United States., Ruff SM; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, United States., Pawlik TM; Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 01; Vol. 15, pp. 1355812. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology, Humans ; Neoadjuvant Therapy ; Immune Checkpoint Inhibitors/therapeutic use ; Combined Modality Therapy |
| مستخلص: | Surgical resection and liver transplant remain the only curative therapies for most patients with hepatocellular carcinoma (HCC). Systemic therapy options have typically been ineffective, but recent advances, such as the combination of immune checkpoint inhibitors and targeted therapies, have shown great promise. Neoadjuvant systemic therapy in resectable or locally advanced HCC is under active investigation with encouraging results in small, early-phase trials. Many of these completed and ongoing trials include combinations of systemic therapy (e.g. immune checkpoint inhibitors, tyrosine kinase inhibitors), transarterial therapies, and radiation. Despite early successes, larger trials with evaluation of long-term oncologic outcomes are needed to determine the role of neoadjuvant systemic therapy in patients with HCC who may be eligible for curative intent surgery or transplant. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Chick, Ruff and Pawlik.) |
| References: | CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902) Vaccine. 2015 Dec 16;33(51):7386-7392. (PMID: 26392010) BMC Cancer. 2021 Mar 23;21(1):301. (PMID: 33757459) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) Clin Cancer Res. 2009 Dec 1;15(23):7412-20. (PMID: 19934295) Front Immunol. 2022 Sep 13;13:998620. (PMID: 36177019) Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229. (PMID: 35065058) Am J Surg. 2019 Jul;218(1):145-150. (PMID: 30224070) Syst Rev. 2019 Nov 7;8(1):264. (PMID: 31699124) N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514) Cancer Cell. 2023 Mar 13;41(3):466-489. (PMID: 36917951) Semin Cancer Biol. 2012 Aug;22(4):275-81. (PMID: 22313874) Cancer Cell Int. 2023 Dec 2;23(1):306. (PMID: 38041068) Hepatol Commun. 2023 Feb 9;7(3):e0054. (PMID: 36757445) Cancers (Basel). 2022 Apr 19;14(9):. (PMID: 35565184) Cell Mol Immunol. 2016 May;13(3):267-76. (PMID: 27063467) Ann Plast Surg. 2009 Jun;62(6):707-9. (PMID: 19461291) Oncoimmunology. 2021 Mar 17;10(1):1900635. (PMID: 33796412) Am Soc Clin Oncol Educ Book. 2016;35:e159-67. (PMID: 27249718) Front Oncol. 2022 Apr 14;12:831407. (PMID: 35494015) Ann Surg Oncol. 2023 Jun;30(6):3166-3169. (PMID: 36897418) Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34103353) Lancet Oncol. 2016 May;17(5):651-62. (PMID: 27055731) Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):435-439. (PMID: 37351140) J Immunother Cancer. 2022 Apr;10(4):. (PMID: 35379737) Expert Rev Gastroenterol Hepatol. 2022 Nov-Dec;16(11-12):1029-1041. (PMID: 36404729) Br J Surg. 2022 Dec 13;110(1):34-42. (PMID: 36346716) Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. (PMID: 32219501) Curr Oncol. 2023 Jun 18;30(6):5863-5875. (PMID: 37366922) Lancet Oncol. 2015 Oct;16(13):1344-54. (PMID: 26361969) Nat Cancer. 2021 Sep;2(9):891-903. (PMID: 34796337) Cancers (Basel). 2023 Jan 18;15(3):. (PMID: 36765557) J Natl Cancer Inst. 2021 Feb 1;113(2):182-191. (PMID: 32497200) Discov Med. 2018 Sep;26(142):85-92. (PMID: 30399326) NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. (PMID: 38319892) Nat Med. 2018 Nov;24(11):1645-1648. (PMID: 30401867) Genome Med. 2023 Sep 18;15(1):72. (PMID: 37723590) J Natl Compr Canc Netw. 2021 May 1;19(5):541-565. (PMID: 34030131) Lancet. 2018 Mar 24;391(10126):1163-1173. (PMID: 29433850) Drug Saf. 2014 Mar;37(3):135-49. (PMID: 24526268) Pragmat Obs Res. 2023 Aug 21;14:63-74. (PMID: 37637511) iScience. 2022 Oct 09;25(11):105317. (PMID: 36310582) J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550) Front Pharmacol. 2017 Aug 23;8:561. (PMID: 28878676) Cancers (Basel). 2023 Aug 04;15(15):. (PMID: 37568782) J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630) Ann Surg. 2020 Sep 1;272(3):481-486. (PMID: 32740235) Nat Commun. 2023 Jun 20;14(1):3650. (PMID: 37339979) Front Immunol. 2022 Sep 26;13:956984. (PMID: 36225934) Cancer Cell. 2022 Nov 14;40(11):1374-1391.e7. (PMID: 36306792) Lancet Oncol. 2019 Jul;20(7):948-960. (PMID: 31160251) Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909) N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792) Br J Cancer. 2019 Jan;120(1):16-25. (PMID: 30413826) Semin Cancer Biol. 2022 Nov;86(Pt 2):834-850. (PMID: 35671877) Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. (PMID: 27323245) Lancet Oncol. 2020 Feb;21(2):294-305. (PMID: 31952975) J Hepatocell Carcinoma. 2023 Feb 08;10:181-191. (PMID: 36789252) Biochem Biophys Res Commun. 2003 Jun 20;306(1):16-25. (PMID: 12788060) Surgery. 2006 Sep;140(3):331-4. (PMID: 16934588) Hepatol Res. 2023 Jul;53(7):649-660. (PMID: 36929310) Front Pharmacol. 2023 Aug 07;14:1225821. (PMID: 37608898) J Exp Clin Cancer Res. 2019 Jun 13;38(1):255. (PMID: 31196207) JAMA Oncol. 2019 Apr 01;5(4):e185896. (PMID: 30629084) Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. (PMID: 35065057) |
| فهرسة مساهمة: | Keywords: hepatocellular carcinoma; immune checkpoint inhibitor; immunotherapy; neoadjuvant; targeted therapy |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240318 Date Completed: 20240319 Latest Revision: 20240412 |
| رمز التحديث: | 20240412 |
| مُعرف محوري في PubMed: | PMC10940409 |
| DOI: | 10.3389/fimmu.2024.1355812 |
| PMID: | 38495884 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1355812 |